Net Income (Loss) Attributable to Parent of Lexaria Bioscience Corp. from 31 Jul 2010 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lexaria Bioscience Corp. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Jul 2010 to 30 Nov 2025.
  • Lexaria Bioscience Corp. Net Income (Loss) Attributable to Parent for the quarter ending 30 Nov 2025 was $1,595,007, a 41% increase year-over-year.
  • Lexaria Bioscience Corp. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Nov 2025 was $10,793,149, a 47% decline year-over-year.
  • Lexaria Bioscience Corp. annual Net Income (Loss) Attributable to Parent for 2025 was $11,901,841, a 105% decline from 2024.
  • Lexaria Bioscience Corp. annual Net Income (Loss) Attributable to Parent for 2024 was $5,795,345, a 13% increase from 2023.
  • Lexaria Bioscience Corp. annual Net Income (Loss) Attributable to Parent for 2023 was $6,664,899, a 8.3% increase from 2022.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Lexaria Bioscience Corp. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $10,793,149 $1,595,007 +$1,108,692 +41% 01 Sep 2025 30 Nov 2025 10-Q 13 Jan 2026 2026 Q1
Q3 2025 $11,901,841 $2,695,838 -$511,048 -23% 01 Jun 2025 31 Aug 2025 10-K 28 Nov 2025 2025 FY
Q2 2025 $11,390,793 $3,789,092 -$2,007,399 -113% 01 Mar 2025 31 May 2025 10-Q 14 Jul 2025 2025 Q3
Q1 2025 $9,383,394 $2,713,212 -$2,063,673 -318% 01 Dec 2024 28 Feb 2025 10-Q 14 Jul 2025 2025 Q3
Q4 2024 $7,319,721 $2,703,699 -$1,524,376 -129% 01 Sep 2024 30 Nov 2024 10-Q 13 Jan 2026 2026 Q1
Q3 2024 $5,795,345 $2,184,790 -$945,471 -76% 01 Jun 2024 31 Aug 2024 10-K 28 Nov 2025 2025 FY
Q2 2024 $4,849,874 $1,781,693 +$589,812 +25% 01 Mar 2024 31 May 2024 10-Q 14 Jul 2025 2025 Q3
Q1 2024 $5,439,686 $649,539 +$648,592 +50% 01 Dec 2023 29 Feb 2024 10-Q 14 Jul 2025 2025 Q3
Q4 2023 $6,088,278 $1,179,323 +$576,621 +33% 01 Sep 2023 30 Nov 2023 10-Q 14 Jul 2025 2025 Q3
Q3 2023 $6,664,899 $1,239,319 +$228,146 +16% 01 Jun 2023 31 Aug 2023 10-K 26 Nov 2024 2024 FY
Q2 2023 $6,893,045 $2,371,505 +$11,420 +0.48% 01 Mar 2023 31 May 2023 10-Q 12 Jul 2024 2024 Q3
Q1 2023 $6,904,465 $1,298,131 +$127,646 +9% 01 Dec 2022 28 Feb 2023 10-Q 12 Jul 2024 2024 Q3
Q4 2022 $7,032,111 $1,755,944 +$237,213 +12% 01 Sep 2022 30 Nov 2022 10-Q 12 Jul 2024 2024 Q3
Q3 2022 $7,269,324 $1,467,465 -$289,373 -25% 01 Jun 2022 31 Aug 2022 10-K 20 Nov 2023 2023 FY
Q2 2022 $6,979,951 $2,382,925 +$183,627 +7.2% 01 Mar 2022 31 May 2022 10-Q 14 Jul 2023 2023 Q3
Q1 2022 $7,163,578 $1,425,777 -$1,818,967 -463% 01 Dec 2021 28 Feb 2022 10-Q 14 Jul 2023 2023 Q3
Q4 2021 $5,344,611 $1,993,157 -$1,283,036 -181% 01 Sep 2021 30 Nov 2021 10-Q 14 Jul 2023 2023 Q3
Q3 2021 $4,061,575 $1,178,092 -$406,386 -53% 01 Jun 2021 31 Aug 2021 10-Q 14 Jan 2022 2022 Q1
Q2 2021 $3,655,189 $2,566,552 -$1,175,899 -85% 01 Mar 2021 31 May 2021 10-Q 14 Jul 2022 2022 Q3
Q1 2021 $2,479,290 $393,190 +$1,390,682 01 Dec 2020 28 Feb 2021 10-Q 11 Apr 2022 2022 Q2
Q4 2020 $3,869,972 $710,121 +$214,641 +23% 01 Sep 2020 30 Nov 2020 10-Q 14 Jan 2022 2022 Q1
Q3 2020 $4,084,613 $771,706 01 Jun 2020 31 Aug 2020 10-K 29 Nov 2021 2021 FY
Q2 2020 $1,390,653 01 Mar 2020 31 May 2020 10-Q 15 Jul 2021 2021 Q3
Q1 2020 $997,492 01 Dec 2019 29 Feb 2020 10-Q 14 Apr 2021 2021 Q2
Q4 2019 $924,762 -$223,371 -32% 01 Sep 2019 30 Nov 2019 10-Q 14 Jan 2021 2021 Q1
Q4 2018 $701,391 -$122,678 -21% 01 Sep 2018 30 Nov 2018 10-Q 09 Jan 2020 2020 Q1
Q4 2017 $578,713 01 Sep 2017 30 Nov 2017 10-Q 11 Jan 2019 2019 Q1
Q4 2015 $411,742 -$13,669 -3.4% 01 Sep 2015 30 Nov 2015 10-Q 08 Jan 2016 2016 Q1
Q4 2014 $398,073 01 Sep 2014 30 Nov 2014 10-Q 08 Jan 2016 2016 Q1
Q1 2012 $603,322 $232,119 -$76,352 -49% 01 Feb 2012 30 Apr 2012 10-Q 07 Jun 2012 2012 Q2
Q4 2011 $526,970 $118,921 +$11,256 +8.6% 01 Nov 2011 31 Jan 2012 10-Q 13 Mar 2012 2012 Q1
Q3 2011 $538,226 $687 01 Aug 2011 31 Oct 2011 10-K 30 Jan 2012 2011 FY
Q2 2011 $252,969 -$223,557 -760% 01 May 2011 31 Jul 2011 10-Q 14 Sep 2011 2011 Q3
Q1 2011 $155,767 01 Feb 2011 30 Apr 2011 10-Q 07 Jun 2012 2012 Q2
Q4 2010 $130,177 01 Nov 2010 31 Jan 2011 10-Q 13 Mar 2012 2012 Q1
Q2 2010 $29,412 01 May 2010 31 Jul 2010 10-Q 14 Sep 2011 2011 Q3

Lexaria Bioscience Corp. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $11,901,841 -$6,106,496 -105% 01 Sep 2024 31 Aug 2025 10-K 28 Nov 2025 2025 FY
2024 $5,795,345 +$869,554 +13% 01 Sep 2023 31 Aug 2024 10-K 28 Nov 2025 2025 FY
2023 $6,664,899 +$604,425 +8.3% 01 Sep 2022 31 Aug 2023 10-K 26 Nov 2024 2024 FY
2022 $7,269,324 -$3,242,318 -81% 01 Sep 2021 31 Aug 2022 10-K 20 Nov 2023 2023 FY
2021 $4,027,006 +$57,607 +1.4% 01 Sep 2020 31 Aug 2021 10-K 28 Nov 2022 2022 FY
2020 $4,084,613 -$8,184,613 -200% 01 Sep 2019 31 Aug 2020 10-K 29 Nov 2021 2021 FY
2019 $4,100,000 -$2,500,000 -38% 01 Sep 2018 31 Aug 2019 10-Q 15 Jul 2021 2021 Q3
2018 $6,600,000 +$8,529,465 01 Sep 2017 31 Aug 2018 10-Q 15 Jul 2021 2021 Q3
2017 $1,929,465 -$652,216 -51% 01 Sep 2016 31 Aug 2017 10-K 14 Nov 2018 2018 FY
2016 $1,277,249 +$706,021 +36% 01 Sep 2015 31 Aug 2016 10-K 14 Nov 2018 2018 FY
2015 $1,983,270 -$423,929 -27% 01 Sep 2014 31 Aug 2015 10-K 27 Nov 2015 2015 FY
2014 $1,559,341 01 Sep 2013 31 Aug 2014 10-K 27 Nov 2015 2015 FY
2011 $538,226 +$14,236 +2.6% 01 Nov 2010 31 Oct 2011 10-K 30 Jan 2012 2011 FY
2010 $552,462 01 Nov 2009 31 Oct 2010 10-K 30 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.